Plasma 25-hydroxycholecalciferol in oral sulfonylurea treated diabetes mellitus.

In oral sulfonylurea treated diabetics, decreased plasma 25-hydroxycholecalciferol and increased activity of bone isoenzyme of serum alkaline phosphatase and urinary hydroxyproline excretion was found when compared with control subjects. In stepwise regression analysis significant relationships were found between bone isoenzyme, urinary hydroxyproline excretion, serum calcium levels and blood glucose levels. The partial correlation and multivariate regression analysis showed that in oral sulfonylurea treated patients, but not in insulin treated patients, the activity of bone isoenzyme of serum alkaline phosphatase was significantly inverse dependent on the 25-hydroxycholecalciferol levels in plasma.

Bone isoenzyme of serum alkaline phosphatase in diabetes mellitus.

Increased activity of bone isoenzyme of serum alkaline phosphatase was found in 52, 82 and 72% of the patients on dietary, oral agents, and insulin regimens, respectively. Significant positive correlations between the activity of bone isoenzyme and urinary hydroxyproline excretion in diabetes are similar to those found in osteoporosis. In stepwise regression analysis, negative correlations were found between the parameters of turnover of bone organic matrix and serum calcium levels; the influence of blood glucose levels in the expression of the biochemical parameters of bone metabolism was most pronounced in patients on oral agents.